A5088578424- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Lung Cancer Research Studies
- Esophageal and GI Pathology
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- Sarcoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Ferroptosis and cancer prognosis
- Cardiac tumors and thrombi
- Pleural and Pulmonary Diseases
- Cancer-related molecular mechanisms research
- Medical Imaging and Pathology Studies
- Pancreatic and Hepatic Oncology Research
- Tracheal and airway disorders
- Multiple and Secondary Primary Cancers
- Vascular Tumors and Angiosarcomas
- Ultrasound in Clinical Applications
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
National Clinical Research
2021-2024
Peking Union Medical College Hospital
2007-2023
Academy of Medical Sciences
2023
National Cancer Center
2021
Fistula Foundation
2020
Peking University
2016
Peking University Cancer Hospital
2016
Huazhong University of Science and Technology
2016
Tongji Hospital
2016
Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine benefits of both to long-term outcomes. Download a PDF the Research Summary. We randomly assigned NSCLC (stage II IIIB [N2 node stage] according eighth edition AJCC Cancer Staging Manual) receive platinum-based chemotherapy plus durvalumab placebo administered intravenously every 3 weeks for 4 cycles before surgery, followed by 12...
Abstract Background: Recent trials have demonstrated the clinical benefit of immunotherapy in either neoadjuvant or adjuvant resectable (R) NSCLC setting. AEGEAN (NCT03800134) is a randomized, double-blind, placebo (PBO)-controlled trial assessing durvalumab (D) + chemotherapy (CT) followed by surgery (Sx) and D patients (pts) with R-NSCLC. Methods: Adults treatment (Tx)-naïve R-NSCLC (stage II-IIIB[N2]; AJCC 8th ed) ECOG PS 0/1 were randomized (1:1) to receive 1500 mg PBO IV platinum-based...
Osteosarcoma is the most common primary bone malignancy, and lung frequent site of metastasis. The limited understanding tumoral heterogeneity evolutionary process genomic alterations in pulmonary metastatic osteosarcoma impedes development novel therapeutic strategies. Here we systematically illustrate disparities between tumors corresponding by multiregional whole-exome whole-genome sequencing 86 tumor regions from 10 patients with osteosarcoma. Metastatic exhibited a significantly higher...
BackgroundIn recent years, a growing number of patients with multiple primary lung cancer (MPLC) are being diagnosed, and subset these is found to have large lesions at the time diagnosis, which referred as 'super MPLC'.MethodsHere, we perform whole exome sequencing (WES) immunohistochemistry (IHC) analysis PD-L1 CD8 on 212 tumor samples from 42 super MPLC.FindingsWe report genomic alteration landscape MPLC. EGFR, RBM10 TP53 mutation TERT amplification important molecular events in evolution...
The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. aim this study was to investigate variation PD-L1 after neoadjuvant and explore association between response, prognosis cancer patients. A total 63 patients who received platinum-based subsequently underwent surgical resection were selected. tumor cells (TC) tumor-infiltrating immune (IC) assessed by immunohistochemistry using...
Purpose: No validated biomarkers that could identify the subset of patients with lung adenocarcinoma who might benefit from chemotherapy have yet been well established. This study aimed to explore potential biomarker model predictive efficacy and survival outcomes after first-line pemetrexed plus platinum doublet based on metabolomics profiling.Experimental Design: In total, 354 consecutive eligible were assigned receive in combination either cisplatin or carboplatin. Prospectively collected...
Abstract Background Small cell lung cancer (SCLC) is lethal and possesses limited therapeutic options. Platinum-based chemotherapy—with or without immune checkpoint inhibitors (anti-PDs)—is the current first-line therapy for SCLCs; however, its associated outcomes are heterogeneous. N 6 -methyladenosine (m A) a novel decisive factor in tumour progression, chemotherapy resistance, immunotherapy response. However, m A modification SCLC remains poorly understood. Methods We systematically...
Multiple primary lung cancer (MPLC) is becoming increasingly common in clinical practice. Imaging examination sometimes difficult to differentiate from intrapulmonary metastasis (IM) or single (SPLC) before surgery. There a lack of effective blood biomarkers as an auxiliary diagnostic method.A total 179 patients who were hospitalized and operated our department January June 2019 collected, they divided into SPLC with 136 patients, MPLC 24 IM 19 patients. In total, 96 healthy people without...
TP53 mutations are the most prevalent detected in non-small-cell lung cancer (NSCLC) and have been revealed as a negative prognostic biomarker of outcome. The impact concomitant ALK-rearranged NSCLC remains uncertain.Tumor samples from 64 patients receiving crizotinib treatment were subjected to next-generation sequencing (NGS) identify mutational status. clinicopathologic features its on effect analyzed.Among patients, 15 (23.4%) showed mutation. Of these, six cases had disruptive nine with...
Abstract Background The role of postoperative radiotherapy in pathological T2–3N0M0 esophageal squamous cell carcinoma is unknown. We aimed to evaluate the efficacy and safety patients with thoracic carcinoma. Materials Methods Patients aged 18–72 years stage after radical surgery without neoadjuvant therapy were eligible. randomly assigned alone or receive 50.4 Gy supraclavicular field 56 mediastinal 28 fractions over 6 weeks. primary endpoint was disease-free survival. secondary endpoints...
Lung adenocarcinoma (LUAD) acts as the representative histological subtype regarding lung cancer, and its mortality morbidity remain high. Therefore, more therapeutic targets are needed. Insulin-like growth factor 2 messenger RNA-binding proteins (IGF2BPs), a class of proteins, including IGF2BP1, IGF2BP2, IGF2BP3, considered to be "reader" N6-methyladenosine (m6A) methylation remarkably affects cancer occurrence development. Studies have shown that IGF2BP3 has prognostic potential in...
Abstract Background: Immune checkpoint inhibitors (ICIs) have been included in various neoadjuvant therapy (NAT) regimens for non-small cell lung cancer (NSCLC). However, due to the relatively short period use of ICIs NAT, patients’ clinical outcomes with different are uncertain. Our study aims examine efficacy immunotherapy (NAIT) NSCLC patients and compare overall survival (OS) event-free (EFS) receiving NAT regimens. Methods: This retrospectively 308 treated subsequent surgery National...
Primary malignant melanoma of the esophagus (PMME) is an extremely rare disease with poor prognosis. We summarized and analyzed characteristics 17 PMME patients (with average age 57.5 ± 10.3 years) who had received surgical resection in our center. The majority (13/17, 76.5%) were male. percentage smoking alcohol consumption was 41.2% 23.5%, respectively. preoperative diagnosis rate 35.3%. Lymph node metastasis mainly involved mid-lower mediastinal upper abdominal area. tumors that invaded...
Objectives: Although low-dose computed tomography has been confirmed to have meaningful diagnostic utility, lung cancer is still the leading cause of cancer-related deaths for both genders worldwide. Thus, a novel panel with stronger performance needed. This study aimed investigate efficacy new in diagnosis.Materials and Methods: The serum levels carcinoembryonic antigen (CEA), 125 (CA125) seven autoantibodies were measured statistically analyzed samples from healthy controls patients...
Non-predominant or even minimal micropapillary and/or solid (MP/S) subtypes have been reported to exert an unfavorable prognostic influence on surgically resected lung adenocarcinoma (ADC). Currently, there is a lack of evidence demonstrate that high-grade pathological subtypes, including MP/S components, impact the prognosis patients with ADCs ground-glass opacity (GGO). In this investigation, we explored implications components in GGO.
Lung adenocarcinoma (LUAD), as the most common histological subtype of lung cancer, is a high-grade malignancy and leading cause cancer-related death globally. Identification biomarkers with prognostic value great significance for diagnosis treatment LUAD. Heterogeneous nuclear ribonucleoprotein C (HNRNPC) an RNA-binding protein "reader" N6-methyladenosine (m6A) methylation, related to progression various cancers; however, its role in LUAD unclear. The aims this study were expression HNRNPC...
Tumor mutational burden (TMB) has both prognostic value in resected non-small cell lung cancer (NSCLC) patients and predictive for immunotherapy response. However, TMB evaluation by whole-exome sequencing (WES) is expensive time-consuming, hampering its application clinical practice. In our study, we aimed to construct a estimation model, with small set of genes, that could precisely estimate WES-TMB and, at the same time, NSCLC patients.TMB model was trained based on genomic data from 1056...